

May 7, 2025

Bureau of Industry and Security  
Office of Strategic Industries and Economic Security  
U.S. Department of Commerce  
[Docket No. 250414-0065]  
XRIN 0694-XC120

Dear Sir or Madam:

The HealthCare Institute of New Jersey (HINJ) is a trade association that serves as the leading voice for our state's research-based biopharmaceutical and medical technology companies. HINJ strives to raise awareness and understanding of New Jersey's and America's global leadership on innovation, expand patient access to the life-saving medical innovations our member companies produce, and preserve New Jersey's and America's workforce, economy and jobs.

Researching, discovering and manufacturing new, life-saving treatments and cures for patients is an extraordinarily complex process that relies on an entire ecosystem of researchers, manufacturers, government agencies and additional partner stakeholders, intertwining R&D and manufacturing facilities, raw materials, FDA-approved suppliers, regulatory reviews and inspections, critical transportation and delivery logistics and infrastructure, and many other vital components. The precise and delicate balance of this multitude of components is extremely challenging to maintain, but those challenges must be met to ensure American patients receive the critical care our companies provide on an hourly basis.

Our national and state innovation ecosystems and the life-saving medical advances they discover are driven by on-going collaborations between and funding from global life sciences companies and small start-ups; colleges and universities; research institutions; hospitals; venture capitalists; and others. Each of these stakeholders contributes significantly to the fight against cancer, heart disease, diabetes, antimicrobial resistance, rare diseases, HIV/AIDS, Alzheimer's and so many other conditions.

As a result of this ecosystem, the life sciences community maintains a significant portion of its R&D and manufacturing operations within the United States, responsible for nearly five million high-paying American jobs and with an annual national economic impact of \$1.7 trillion. Recent industry announcements reflect an even further increase in investment in the United States.

While these supply and distribution chains, partnerships and collaborations, and logistical infrastructures take years to assemble and integrate, ensuring other countries pay their fair share while lowering costs for American patients is a goal we've long shared. However, changes to US tariff policies could unintentionally impact this ecosystem, hampering America's ability to research and discover new treatments and cures while increasing costs of medicines and medical devices.

America's patient community relies on New Jersey's life sciences to continue doing what we do best – saving lives around the world by finding new treatments and cures right here in New Jersey. Our comments here are offered to preserve that ability and protect America's national interests and global leadership.

Respectfully,



Chrissy Buteas  
President and Chief Executive Officer